Back to Search
PAUL MUSTO, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1699758896IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
50948(MA)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
MICHIGAN STATE UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE
Class of 1977
Research & Publications (20)
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective.
PMID 19663768·Curr Drug Targets·2009
6-review
Role of thalidomide in previously untreated patients with multiple myeloma.
PMID 18925849·Expert Rev Anticancer Ther·2008
6-review
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
PMID 18683218·Cancer·2008
3-trial
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
PMID 17320951·Leuk Res·2007
4-observational
Efficacy and safety of bortezomib in patients with plasma cell leukemia.
PMID 17469169·Cancer·2007
8-other
Melphalan: old and new uses of a still master drug for multiple myeloma.
PMID 17714032·Expert Opin Investig Drugs·2007
6-review
Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
PMID 16219350·Leuk Res·2006
2-rct
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
PMID 16111749·Leuk Res·2006
3-trial
Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.
PMID 15638854·Br J Haematol·2005
8-other
Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes.
PMID 15989709·Clin Lymphoma·2005
4-observational
Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
PMID 15360005·Leuk Lymphoma·2004
5-case
Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.
PMID 15109529·Leuk Res·2004
6-review
Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes.
PMID 12846896·Br J Haematol·2003
3-trial
Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial.
PMID 14565658·Leuk Lymphoma·2003
3-trial
Hepatitis C virus infection and B-cell non-Hodgkin's lymphomas: more than a simple association.
PMID 12521391·Clin Lymphoma·2002
6-review
Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes.
PMID 12161367·Haematologica·2002
8-other
Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
PMID 11146570·Haematologica·2001
8-other
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
PMID 19638460·Clin Cancer Res·2009
3-trial
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
PMID 19641526·Leukemia·2009
3-trial
Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
PMID 19509142·Clin Cancer Res·2009
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 51 PERFORMANCE DR, SUITE 110
WEYMOUTH, MA 02189 - Phone
- (617) 769-1162
Quick Facts
- NPI
- 1699758896
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 49
- Publications
- 20
Are you this provider?
Claim Your Profile